KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Investments (2016 - 2025)

Biomarin Pharmaceutical's Long-Term Investments history spans 17 years, with the latest figure at $492.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments fell 5.56% year-over-year to $492.2 million, compared with a TTM value of $492.2 million through Dec 2025, down 5.56%, and an annual FY2025 reading of $492.2 million, down 5.56% over the prior year.
  • Long-Term Investments for Q4 2025 was $492.2 million at Biomarin Pharmaceutical, down from $512.9 million in the prior quarter.
  • The five-year high for Long-Term Investments was $620.6 million in Q1 2024, with the low at $321.1 million in Q1 2021.
  • Average Long-Term Investments over 5 years is $469.7 million, with a median of $499.5 million recorded in 2025.
  • Year-over-year, Long-Term Investments crashed 34.26% in 2022 and then soared 83.06% in 2023.
  • Tracing BMRN's Long-Term Investments over 5 years: stood at $507.8 million in 2021, then crashed by 34.26% to $333.8 million in 2022, then soared by 83.06% to $611.1 million in 2023, then fell by 14.71% to $521.2 million in 2024, then decreased by 5.56% to $492.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Long-Term Investments are $492.2 million (Q4 2025), $512.9 million (Q3 2025), and $508.6 million (Q2 2025).